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Glucosylceramides (GlcCer) and ceramides (Cer) appear
to have opposite effects on epidermal growth and differ-
entiation. Whereas Cer inhibit mitosis and induce ter-
minal differentiation and apoptosis in cultured
keratinocytes, GlcCer is mitogenic in young murine
epidermis. Using a recently described murine model of
chronologic senescence we explored whether GlcCer is
mitogenic in aged epidermis. Epidermal GlcCer content
increases following topical applications of either conduri-
tol-B epoxide (CBE), an inhibitor of GlcCer hydrolysis,
or exogenous GlcCer in a penetration-enhancing vehicle.
During chronologic aging in the hairless mouse, baseline
epidermal DNA synthesis rates remain normal until
18 mo, but decline significantly at 24 mo. Topical CBE
stimulates a 1.5- to 1.9-fold increase in epidermal DNA
synthesis in all age groups (i.e., 1–2, 18, and 24 mo).
Although the CBE induced increase in [3H]thymidine
incorporation in 24 mo old animals is significant
(p , 0.01), it is not sufficient to reach the absolute levels
reached in similarly treated, younger mouse epidermis.
Sphingolipids are emerging as a novel family of lipid secondmessengers, which mediate diverse effects on growth, differ-entiation, and apoptosis in several cell types and tissues.Whereas sphingoid bases, related lysosphingolipid species,and ceramides (Cer) generally (reviewed in Kolesnick, 1991;
Hannun, 1996), but not always (Olivera et al, 1992), inhibit mitosis
and induce differentiation, other sphingoid base metabolites, such as
glucosylceramides (GlcCer) (Datta and Radin, 1988; Shayman et al,
1991; Marsh et al, 1995), lysosphingomyelin (Desai and Spiegel, 1991),
lactosylceramide (Chatterjee, 1991), and more complex glycosphingo-
lipids (Tsuji et al, 1983; Katoh-Semba et al, 1986; Hanai et al, 1988),
can stimulate growth. For example, the organomegaly in Gaucher
disease reflects not only tissue accumulation of GlcCer (Barranger and
Ginns, 1989), but also putative growth-stimulatory effects of GlcCer
(Datta and Radin, 1988). Moreover, the kidney hypertrophy that
occurs in experimental diabetes is reversed by inhibitors of GlcCer
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Moreover, topical GlcCer induced mitogenesis is both
dose dependent and hexose specific in young (1–2 mo
old) animals, and remains effective in aged (ø24 mo old)
animals. Furthermore, the CBE induced increase in DNA
synthesis in aged epidermis is sufficient to produce epi-
dermal hyperplasia. Finally, although an increased
GlcCer:Cer ratio can alter stratum corneum barrier func-
tion and membrane structure, neither stratum corneum
function nor extracellular membrane structure change
under these experimental conditions, and therefore the
mitogenic effects of increased epidermal GlcCer cannot
be attributed to effects on the stratum corneum. These
results show that: (i) elevations in endogenous GlcCer
are mitogenic for aged as well as young murine epidermis;
(ii) topical GlcCer is also mitogenic when delivered
in an enhancing vehicle; and (iii) despite the putative
importance of epidermal DNA synthesis for barrier
homeostasis, these mitogenic alterations do not alter
stratum corneum function. Key words: aging/ceramides/
epidermal DNA synthesis/Gaucher disease. J Invest Dermatol
110:383–387, 1998
synthase in association with declining tissue levels of GlcCer (Zador
et al, 1993). In addition, experimentally induced increases in GlcCer
by either inhibition of GlcCer hydrolysis (Hara and Radin, 1979;
Shayman et al, 1991) or direct injection of GlcCer (Datta and Radin,
1988), enhance tissue proliferation. We recently showed similarly
that either inhibition of β-glucocerebrosidase with topical conduritol
compounds, or intracutaneous administration of exogenous GlcCer,
results in epidermal hyperproliferation in young hairless mice (Marsh
et al, 1995). Furthermore, the growth stimulatory properties of the
β-glucocerebrosidase inhibitors correlate with accumulation of GlcCer
in the mitotically active, basal layers of the epidermis, and are
independent of effects on barrier function or initiation of inflammation
(Marsh et al, 1995). These studies suggest that GlcCer and Cer perform
opposite growth and differentiation related functions in the epidermis,
with the tissue normally maintaining a balance in these two sphingo-
lipids.
Skin aging is accompanied by well-characterized abnormalities in
the dermis, e.g., photoaging associated collagen and proteoglycan
proteolysis with elastosis (Balin and Kligman, 1989a). In contrast, little
is known about changes in the epidermis with chronologic aging.
Although epidermal proliferation declines with chronologic aging
(Balin and Kligman, 1989b; Cerimele et al, 1990; Haratake et al, 1997),
the biochemical and molecular basis for this change is not known. In
addition, the epidermal permeability barrier is also compromised with
advanced chronologic aging (Ghadially et al, 1995), an abnormality
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attributed to the defective generation of epidermal lipids (Ghadially
et al, 1995). It is possible that reduced epidermal growth rates contribute
to declining lipid generation and deposition, because mitogens such as
alpha-hydroxyacids reverse many features of chronologic and photo-
aging. In this study, we asked whether modulation of epidermal GlcCer
content with topical administration of either conduritol inhibitors or
GlcCer would enhance epidermal growth in aged epidermis. Our
studies show that both approaches stimulate epidermal growth in aged
epidermis, suggesting that reduced GlcCer could contribute to the
functional alterations in cutaneous aging.
MATERIALS AND METHODS
Materials Glucocerebrosides (Gaucher spleen) were obtained from Matreya
(Philadelphia, PA); conduritol B epoxide (CBE) was from Toronto Research
Chemicals (Toronto, Canada). Calf thymus DNA was obtained from Sigma
(St. Louis, MO), dithiothreitol was obtained from Boehringer (Indianapolis,
IN), and [methyl-3H] thymidine was from Amersham Life Sciences (Arlington
Heights, IL). All solvents were reagent or high performance liquid chromato-
graphy grade.
Animals and experimental protocols Male hairless mice (h/h) from Charles
River (Hollister, CA) were used in these studies, because these animals live
to ù 24 mo of age without premature development of tumors (Ghadially et al,
1995), as occurs with other commercially available hairless murine strains.
Cohorts of mice were studied between 1 and 2, 18, or 24 mo of age, because
prior studies showed that abnormal epidermal function does not occur in these
animals until ù 18 mo (Ghadially et al, 1995). Animals were treated with either
(i) a single, daily topical application of CBE (100 µg) or (ii) monohexosyl-
ceramides [GlcCer or galactosylCer (GalCer)], 2.5 mg twice daily in a propylene
glycol:ethanol (PG:EtOH; 7:3 vols) or a penetration-enhancing vehicle (Cellegy
Pharmaceuticals, San Carlos, CA) applied to a 2.5 cm2 area of one flank. The
opposite flank was left either untreated or was treated with vehicle alone.
Additional groups of animals were treated with GlcCer at doses of 0.5, 1.0,
2.0, or 2.5 mg twice daily in the penetration-enhancing vehicle, which proved
to be more effective than PG:EtOH.
Epidermal DNA synthesis Twenty-four hours after the initial treatment,
animals were sacrificed and flank skin removed. Both treated and control skin
samples were scraped free of excess subcutaneous fat, and 6 mm punch samples
were placed into 1.0 ml of serum-free, keratinocyte growth medium (Clonetics,
San Diego, CA). One microcurie of [3H]thymidine was added to each well,
and tissue samples were incubated at 37°C for 2 h. Samples were rinsed three
times with phosphate-buffered saline, homogenized in phosphate-buffered
saline, and an equal volume of cold trichloroacetic acid (20% by weight) was
added. The pellet was rinsed twice with cold 5% trichloroacetic acid, resuspended
in 1N NaOH, and aliquots were counted by liquid scintillation spectrometry.
Total cellular DNA was assayed by the method of Labarca and Paigan (1980).
Samples for DNA assay were brought to 1 ml with Hoechst buffer (pH 7.4).
One milliliter of bisbenzimidazole (Sigma; diluted 1:1000 with distilled H2O)
was added. Standards were prepared using calf thymus DNA (137 µg per ml)
diluted 1:10 with Hoechst buffer. All samples and standards were kept in the
dark for 2 h, and fluorescence was measured using a spectrophotometer.
Statistical differences were calculated using a Student’s two-tailed t test.
Histology Fresh, full-thickness skin samples were obtained before treatment,
and at day 5, following alternate-day treatment (i.e., days 1, 3, and 5) with
CBE or vehicle. The alternate-day regimen was used to accentuate the histologic
evidence for hyperplasia (subsequent to the induced hyperproliferation at 24 h
following a single application), without evidence for deleterious effects on
barrier integrity [i.e., no change in transepidermal water loss (TEWL) occur
with this regimen]. Biopsies were taken for light microscopy (hematoxylin and
eosin stain), fixed in buffered formalin, paraffin-embedded, and sectioned
(5 µm). All sections were examined and photographed with a Leitz Ortholux
II microscope.
Assessment of stratum corneum function Cohorts of aged (24 mo) and
young (1–2 mo) mice were treated with either the GlcCer in vehicle or vehicle
alone twice daily, on days 1, 3, and 5 as above. Immediately after the last
application of lipid versus vehicle, the stratum corneum of treated and untreated
sites was stripped successively with cellophane tape until TEWL rates exceeded
6 mg per cm2 per h. The number of strippings required to reach this level of
barrier abrogation was considered an indicator of stratum corneum integrity
(5 cohesion). After tape-stripping, barrier function was measured at regular
intervals until function had normalized, utilizing an electrolytic water analyzer
(Meeco, Warrington, PA), as described previously (Holleran et al, 1991). Water
loss measurements were obtained over a small area of skin (0.5 cm2), recorded
Figure 1. Stimulation of [3H]thymidine incorporation by topical CBE
in young versus aging epidermis. Twenty-four hours following initial
treatment with CBE, whole skin punch biopsy samples were incubated with
[3H]thymidine in organ culture (see Materials and Methods). Baseline (vehicle
treated) incorporation was significantly diminished in 24 mo old animals
(*p , 0.01 versus either 1–2 or 18 mo old animals). Increased incorporation
was observed in all animals treated with CBE regardless of age [significance for
CBE versus vehicle treated samples for each age group: a, p , 0.005 (n 5 12);
b, p , 0.001 (n 5 25); and c, p , 0.01 (n 5 6), for 1–2, 18, and . 24 mo
old animals, respectively]. Results are presented as mean [3H]-incorporated
disintegrations per min (DPM) per cm2 6 SEM.
in parts per million per 0.5 cm2 per h over background, and the data converted
to mg per cm2 per h. At each time point, 3–5 readings were performed on
each flank (treated, vehicle treated, and untreated), with 6–8 animals in each
test group.
Electron microscopy In order to assess whether the mitogenic response of
aged epidermis to CBE or GlcCer could be attributed to stimulation of DNA
synthesis secondary to altered barrier function, we obtained full thickness skin
biopsies for electron microscopy at 24 h and at day 5 following alternate-day
treatments (i.e., days 1, 3, and 5, as above). Samples were fixed in half-strength
Karnovsky’s fixative, divided, and processed through reduced 1.0% osmium
tetroxide or 0.25% ruthenium tetroxide (Hou et al, 1991), followed by
embedding in an Epon-epoxy mixture (McNutt and Crain, 1981). Full-
thickness biopsies from the flanks of both aged (. 18 mo) and young (6–8 wk
old) hairless mice were also processed, as described above. Ultrathin sections
were viewed in an electron microscope (10 A; Carl Zeiss, Thornwood, NY)
after further contrasting in lead citrate and uranyl acetate.
RESULTS
Inhibition of β-glucocerebrosidase stimulates mitogenesis in
aged mouse epidermis Inhibition of epidermal β-glucocerebrosid-
ase with CBE is accompanied by increased DNA synthesis and
epidermal hyperplasia, with localized accumulation of GlcCer in young
murine epidermis (Marsh et al, 1995). Therefore, we first assessed
whether aged epidermis would display a comparable response to topical
CBE treatment. As seen in Fig 1, young (1–2 mo) murine epidermis
displays a 50% increase (i.e., 1.5-fold) in DNA synthesis after two
topical applications of CBE versus vehicle (p , 0.005). Moreover,
18 mo old epidermis also displays rates of DNA synthesis that are still
comparable with young epidermis in vehicle treated sites, and the
epidermis generates a 90% increase in DNA synthesis with CBE versus
vehicle treatment (p , 0.001). By 24 mo, basal rates of epidermal DNA
synthesis are depressed significantly (50% reduction) in comparison with
rates in young and 18 mo old skin (p , 0.01). Nevertheless, 24 mo
old epidermis also responds to CBE treatment with a 90% increase in
DNA synthesis; however, the increase at 24 mo is not sufficient to
attain the absolute rates reached in 1–2 or 18 mo epidermis treated
with CBE. These results confirm the mitogenic response to CBE in
young murine epidermis, show that epidermal DNA synthesis does
not decline until after 18 mo in murine skin, and show that aged
epidermis generates a mitogenic response comparable with young
epidermis, but that the response in 24 mo skin does not attain levels
comparable with those in younger epidermis.
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Figure 2. Stimulation of [3H]thymidine incorporation by topical GlcCer
in young (1–2 mo old) murine epidermis. Twenty-four hours following
topical application of vehicle, penetration-enhancing vehicle (enhancer), or
enhancer plus either GlcCer or GalCer (each 2.5 mg), punch biopsy samples
were incubated in organ culture with [3H]thymidine as described (see Materials
and Methods). Topical GlcCer treatment significantly increased incorporation
over vehicle or enhancer treated controls in young epidermis (p , 0.001; n 5
6); topical GalCer did not alter incorporation relative to controls. The
penetration-enhancing vehicle (see Materials and Methods) did not significantly
alter baseline rate of incorporation. Results presented as mean DPM per
cm2 6 SEM.
Figure 3. Mitogenic effect of topical GlcCer is dose dependent. Increasing
amounts of topical GlcCer (0.5–2.5 mg) were applied to flanks of young (1–
2 mo) mice. Punch biopsies and thymidine incorporation were performed as
described above. Increasing amounts of topical GlcCer corresponded with
increased stimulation of epidermal mitogenesis (thymidine incorporation) 24 h
following initial application. *For 2.5 mg GlcCer dose, p , 0.005 (n 5 4
animals) versus vehicle-enhancer control (n 5 14); values are mean 6 SD.
Lower GlcCer doses (0.5, 1.0, 2.0 mg) were performed on duplicate animals
only (n 5 2), and reported as average 6 range/2.
Topical glucosylceramides stimulate mitogenesis in young and
aged mouse epidermis Intracutaneous injections of GlcCer (but
not other cerebrosides) were shown to stimulate DNA synthesis in
young murine epidermis (Marsh et al, 1995). Because topical applications
of GlcCer in a standard, PG:EtOH vehicle were not effective in
mimicking this effect (not shown), we next ascertained whether GlcCer
would stimulate mitogenesis, if applied from a penetration-enhancing
vehicle expected to improve penetration through the stratum corneum.
As shown in Fig 2, topical GlcCer stimulated an approximately 2-fold
increase in epidermal DNA synthesis in comparison with both the
enhancing and the standard vehicles. In addition, the effect of the
sphingolipid is hexose specific, i.e., as described previously in young
murine skin for intracutaneous GalCer (Marsh et al, 1995), no response
occurs with topical GalCer in young murine skin (Fig 2). Moreover,
the highest response (2.0-fold increase) occurs at a final dose of 2.5 mg,
whereas lower doses produced lesser increases in DNA synthesis (Fig 3).
Figure 4. Topical GlcCer stimulates [3H]thymidine incorporation in
aged (24 mo) epidermis. Topical GlcCer (2.5 mg) was applied to the back
of either young (1–2 mo) or aged (. 24 mo old) mice as before (Fig 2).
Whole skin punch biopsy samples were taken 24 h following the initial
application of penetration-enhancing vehicle (control), or enhancer plus GlcCer
(2.5 mg), incubated in organ culture with [3H]thymidine. Both young (1.5-
fold) and aged (1.6-fold) murine epidermis demonstrated significantly enhanced
thymidine incorporation over vehicle treated control samples (p , 0.005 for
each; n 5 5 animals). Values are mean 6 SD.
We next determined whether topical GlcCer application would
result in an increased mitogenic response in aged animal epidermis.
Topical GlcCer induces a significant increase in epidermal mitogenesis
both in young (1–2 mo old) and in aged (. 24 wk old) murine
epidermis (Fig 4). Moreover, despite the lower baseline mitogenic
rate in aged animal epidermis, the fold-increase in [3H]thymidine
incorporation is equivalent for young and aged animals (i.e., 1.5- to
1.6-fold), and comparable with the increase induced with CBE in aged
skin. These results show that topical GlcCer is able to stimulate
epidermal DNA synthesis, in a concentration, vehicle, and hexose
dependent fashion, regardless of age.
Inhibition of β-glucocerebrosidase leads to hyperplasia of aged
murine epidermis Because topical conduritol compounds produce
both increased epidermal DNA synthesis and epidermal hyperplasia in
young murine skin (compare with Fig 1; Marsh et al, 1995), we
determined whether CBE produced a similar hyperplasia response in
aged animals. Following twice-daily applications of CBE on alternate
days for 5 d, aged epidermis displays an increased number of cell layers
in comparison with adjacent vehicle treated sites (Fig 5). The alternate-
day regimen was used to accentuate hyperplasia; no change in TEWL
was evident with this regimen. Moreover, there is no evidence of
inflammatory cells in the dermis following CBE treatment, supporting
earlier studies that CBE induced epidermal hyperplasia cannot be
attributed to nonspecific irritant effects (Marsh et al, 1995).
Prior studies have also shown both that barrier function regulates
epidermal DNA synthesis (Proksch et al, 1991) and that chronic, single-
daily treatment (topical BrCBE for . 5 d; Holleran et al, 1993, 1994),
or chronic, twice-daily treatment (CBE for . 3 d; Marsh et al, 1995),
can abrogate epidermal barrier function. The above studies show that
alternate-day CBE treatment (i.e., days 1, 3, and 5) does not alter
barrier function (no change in TEWL) in aged epidermis. Using this
modified regimen, we next determined whether CBE treatment
alters stratum corneum membrane structure, as a further, independent
indicator of barrier dysfunction. Neither CBE nor vehicle treatment
modified membrane structure in aged stratum corneum during the
course of these studies (not shown). Although the overall content of
intercellular lamellae is decreased in both groups, as described previously
for aged murine stratum corneum (Ghadially et al, 1995), normal
lamellar unit structures predominate in both groups (not shown). These
studies, together with the TEWL assays above, show that CBE modifies
neither stratum corneum structure nor function during the course of
these studies.
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Figure 5. Histology of CBE treated aged (24 mo old) epidermis.
Hematoxylin and eosin stain of vehicle treated (A) and CBE treated (B) aged
murine skin. Skin was treated with topical CBE on alternate days (i.e., day 1,
3, and 5) (see Materials and Methods). Hyperplasia is evident in CBE treated
epidermis (B), whereas vehicle treated controls appear normal (A). · · · · ·,
dermal–epidermal junction; d, dermis; magnification, 3 150; scale bar, 20 µm.
CBE induced enhancement of epidermal DNA synthesis does
not lead to improvement in stratum corneum function Prior
studies have shown that barrier function is an important regulator of
epidermal DNA synthesis (Proksch et al, 1991); however, whether the
enhanced DNA synthesis after acute insults is required for barrier
recovery is not known. Because aged murine epidermis displays both
defective stratum corneum cohesion and barrier recovery (Ghadially
et al, 1995), we next examined whether the CBE induced enhancement
of epidermal DNA synthesis improves stratum corneum function.
Cohorts of 24 mo old mice were treated (days 1, 3, and 5) with either
CBE or vehicle, conditions that increase DNA synthesis about 2-fold
(compare with Fig 1). On the fifth day, baseline stratum corneum
barrier function was measured, followed by sequential tape stripping
as a measure of integrity, and TEWL was measured again at several
time points after tape stripping (barrier recovery). This CBE treatment
regimen did not result in altered barrier function in aged epidermis
(i.e., no change from baseline; not shown), similar to that reported
previously for young murine skin following 1–3 d of daily CBE
(Holleran et al, 1993; Marsh et al, 1995). Moreover, the number of
strippings required to reach a TEWL ù 8 mg per cm2 per h was
not significantly different in the CBE versus vehicle treated groups
(approximately four strippings in each group). Finally, the kinetics of
barrier recovery were comparable in the CBE versus vehicle treated,
aged animals (not shown).
DISCUSSION
In the stratum corneum of terrestrial mammals, ceramides are generated
from GlcCer precursors by the activity of β-glucocerebrosidase (Wertz
and Downing, 1989; Holleran et al, 1992), a process critical for normal
permeability barrrier homeostasis (Holleran et al, 1993, 1994); however,
GlcCer also appear to have other important, independent regulatory
roles in epidermal homeostasis. For example, we demonstrated previ-
ously that increased epidermal GlcCer induces hyperplasia in young
murine epidermis (Marsh et al, 1995). Studies in cultured keratinocytes
have also shown that GlcCer synthase inhibitors slow growth (Wakita
et al, 1994)1, whereas β-glucocerebrosidase inhibitors stimulate growth;
however, excess GlcCer is readily hydrolyzed to Cer, to restore basal
growth kinetics to cultured keratinocytes.1 This study demonstrates
that aged murine epidermis retains its sensitivity to the mitogenic
effects of GlcCer, providing further evidence that sphingolipids can
have additional effects in the regulation of epidermal homeostasis.
Chronologic aging of mammalian skin is associated with several
alterations, including a well-known decrease in epidermal turnover
(Balin and Kligman, 1989b; Cerimele et al, 1990). Aged murine
epidermis not only demonstrates a diminished baseline [3H]thymidine
incorporation and epidermal thickness, but also an attenuated mitotic
response to high-dose UVB exposure (Haratake et al, 1997). In this
study, aged murine epidermis (i.e., . 24 wk old), despite its lower
baseline epidermal proliferation rates, retains its responsiveness to the
pro-mitogenic effects of increased epidermal GlcCer. Both endogenous
manipulation of GlcCer (i.e., CBE inhibition of GlcCer hydrolysis)
and exogenous application of GlcCer (i.e., subcutaneous injection or
topical application) results in a nearly equivalent increase in epidermal
proliferation. The epidermal GlcCer response was also found to be
dose dependent (this study), specific for the glucose-containing Cer (i.e.,
galactosyl-Cer does not show mitogenic effects), and a consequence
of neither inflammation nor permeability barrier disruption (Marsh
et al, 1995).
The physiologic role of GlcCer in the epidermis and other tissues
remains unresolved, as does their mechanism of action. Nevertheless,
the results presented here and previously (Marsh et al, 1995) suggest
that cellular GlcCer levels are at least permissive in the regulation of
epidermal proliferation. These results also suggest that the ichthyotic
skin findings in both human and murine β-glucocerebrosidase defi-
ciency may result, in part, from excessive GlcCer in the epidermis
(Holleran et al, 1994; Sidransky et al, 1996). Our results mirror
comparable studies in other Gaucher tissues, where the lack of
β-glucocerebrosidase also results in abnormally elevated GlcCer levels in
association with organomegaly (Barranger and Ginns, 1989). Moreover,
pharmacologic manipulations of cellular and tissue GlcCer levels in
the whole animal also appear to mimic the organomegaly associated
with Gaucher disease (Hara and Radin, 1979; Datta and Radin, 1988;
Holleran et al, 1994). Whether high turnover, actively dividing cells,
in general, exhibit higher levels of GlcCer relative to quiescent cells
has not yet been addressed; however, inhibition of GlcCer synthesis
has been associated with anti-tumor activity (Inokuchi et al, 1987).
Furthermore, elevated cellular GlcCer has recently been correlated
with multidrug resistance in cancer cells (Lavie et al, 1996), and
treatment of resistant MCF-7 human breast cancer cells with the
GlcCer synthase inhibitor, PDMP, restores sensitivity to adriamycin
(Lavie et al, 1997); however, despite the elevated serum and tissue
GlcCer levels in Gaucher patients, a higher risk of aggressive cancer
or metastasis has not been reported for this patient population.
An increasing variety of regulatory effects has been attributed
to other glycosylated and nonglycosylated sphingolipid metabolites.
Exogenously supplied Cer, in general, inhibit cellular proliferation and
induce differentiation and/or apoptosis (Okazaki et al, 1990; Kolesnick,
1991; reviewed in Hannun, 1996). Likewise, proliferation of cultured
keratinocytes is inhibited similarly (Wakita et al, 1994).1 Conversely,
and in accordance with this study, increased GlcCer accelerates the
growth of cultured human keratinocytes; however, at higher GlcCer
concentrations, Cer accumulates due to GlcCer hydrolysis, leading to
significant inhibition of keratinocyte proliferation.1 Taken together,
1Uchida Y, Schmuth M, Elias PM, Holleran WM: Divergent effects of
ceramides and glucosylceramides on human keratinocyte proliferation.
Submitted.
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these results suggest that GlcCer and Cer may have opposing roles in
the regulation of cellular proliferation.
Lactosylceramide, which contains the GlcCer core structure with
an additional galactose residue, stimulates aortic smooth muscle cell
proliferation (Chatterjee, 1991), an effect that appears to involve MAP
kinase activation (Bhunia et al, 1996). Furthermore, the stimulatory
effects of GlcCer in proximal tubular cells of polycystic kidney disease
have been attributed to conversion of GlcCer to lactosyleramide by a
specific galactosyltransferase (Chatterjee et al, 1996). Whether the
effects of GlcCer on intact murine epidermis described here require
prior conversion to lactosylceramide has yet to be determined.
Finally, the N-deacylated metabolite of sphingomyelin, or sphingos-
ylphosphorylcholine, is not only elevated in the stratum corneum of
atopic dermatitis patients (Murata et al, 1996), but also has pro-
mitogenic effects in several cell types (Desai and Spiegel, 1991),
including dermal 3T3 fibroblasts and endothelial cells (Sun et al, 1996).
In addition, in healing-impaired diabetic mice, sphingosylphosphoryl-
choline treatment improves wound healing and increases mitotic
activity in cells of the basal epidermal layer (Sun et al, 1996). Although
the mechanism by which sphingosylphosphorylcholine effects cellular
activities has not been fully delineated, calcium mobilization and
arachidonic acid release appear to be involved (Ghosh et al, 1990;
Desai et al, 1993; Kindman et al, 1994).
In summary, we have shown that modulation of epidermal GlcCer
content with either β-glucocerebrosidase inhibitors, such as CBE, or
with GlcCer itself can enhance epidermal growth in both young and
aged epidermis. These results suggest that manipulation of the levels
of epidermal ceramide metabolites may be a novel approach to
regulating epidermal turnover and homeostasis in appropriate disease
states.
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